Glaxosmithkline Plc Adr Stock Fundamentals
| GSK Stock | USD 36.17 0.38 1.04% |
GlaxoSmithKline PLC ADR fundamentals help investors to digest information that contributes to GlaxoSmithKline PLC's financial success or failures. It also enables traders to predict the movement of GlaxoSmithKline Stock. The fundamental analysis module provides a way to measure GlaxoSmithKline PLC's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to GlaxoSmithKline PLC stock.
At this time, GlaxoSmithKline PLC's Discontinued Operations is quite stable compared to the past year. Extraordinary Items is expected to rise to about 12.7 B this year, although the value of Gross Profit will most likely fall to about 14.6 B. GlaxoSmithKline | Select Account or Indicator |
GlaxoSmithKline PLC ADR Company Profit Margin Analysis
GlaxoSmithKline PLC's Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.
Current GlaxoSmithKline PLC Profit Margin | 0.08 % |
Most of GlaxoSmithKline PLC's fundamental indicators, such as Profit Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, GlaxoSmithKline PLC ADR is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
GlaxoSmithKline Profit Margin Historical Pattern
Today, most investors in GlaxoSmithKline PLC Stock are looking for potential investment opportunities by analyzing not only static indicators but also various GlaxoSmithKline PLC's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's profit margin growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of GlaxoSmithKline PLC profit margin as a starting point in their analysis.
GlaxoSmithKline PLC Profit Margin |
| Timeline |
In a nutshell, Profit Margin indicator shows the amount of money the company makes from total sales or revenue. It can provide a good insight into companies in the same sector, as well as help to identify trends of a company from year to year.
| Competition |
GlaxoSmithKline Pretax Profit Margin
Pretax Profit Margin |
|
Based on the latest financial disclosure, GlaxoSmithKline PLC ADR has a Profit Margin of 0.0821%. This is 100.73% lower than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The profit margin for all United States stocks is 106.46% lower than that of the firm.
GlaxoSmithKline PLC ADR Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining GlaxoSmithKline PLC's current stock value. Our valuation model uses many indicators to compare GlaxoSmithKline PLC value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across GlaxoSmithKline PLC competition to find correlations between indicators driving GlaxoSmithKline PLC's intrinsic value. More Info.GlaxoSmithKline PLC ADR is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers reporting about 0.30 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for GlaxoSmithKline PLC ADR is roughly 3.29 . At this time, GlaxoSmithKline PLC's Return On Equity is quite stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value GlaxoSmithKline PLC by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.GlaxoSmithKline Profit Margin Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses GlaxoSmithKline PLC's direct or indirect competition against its Profit Margin to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of GlaxoSmithKline PLC could also be used in its relative valuation, which is a method of valuing GlaxoSmithKline PLC by comparing valuation metrics of similar companies.GlaxoSmithKline PLC is currently under evaluation in profit margin category among its peers.
GlaxoSmithKline PLC ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, GlaxoSmithKline PLC's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to GlaxoSmithKline PLC's managers, analysts, and investors.Environmental | Governance | Social |
GlaxoSmithKline Fundamentals
| Return On Equity | 0.23 | ||||
| Return On Asset | 0.0693 | ||||
| Profit Margin | 0.08 % | ||||
| Operating Margin | 0.10 % | ||||
| Current Valuation | 90.03 B | ||||
| Shares Outstanding | 2.04 B | ||||
| Shares Owned By Insiders | 0.12 % | ||||
| Shares Owned By Institutions | 16.99 % | ||||
| Number Of Shares Shorted | 17.43 M | ||||
| Price To Earning | 11.80 X | ||||
| Price To Book | 4.34 X | ||||
| Price To Sales | 2.35 X | ||||
| Revenue | 30.33 B | ||||
| Gross Profit | 22.53 B | ||||
| EBITDA | 9.14 B | ||||
| Net Income | 4.93 B | ||||
| Cash And Equivalents | 3.72 B | ||||
| Cash Per Share | 0.32 X | ||||
| Total Debt | 18.02 B | ||||
| Debt To Equity | 0.98 % | ||||
| Current Ratio | 1.43 X | ||||
| Book Value Per Share | 3.35 X | ||||
| Cash Flow From Operations | 6.77 B | ||||
| Short Ratio | 4.24 X | ||||
| Earnings Per Share | 1.55 X | ||||
| Price To Earnings To Growth | 0.81 X | ||||
| Target Price | 43.42 | ||||
| Beta | 0.34 | ||||
| Market Capitalization | 73.82 B | ||||
| Total Asset | 59.01 B | ||||
| Retained Earnings | 7.24 B | ||||
| Working Capital | (2.42 B) | ||||
| Current Asset | 16.59 B | ||||
| Current Liabilities | 13.42 B | ||||
| Annual Yield | 0.04 % | ||||
| Five Year Return | 5.32 % | ||||
| Net Asset | 59.01 B | ||||
| Last Dividend Paid | 0.61 |
About GlaxoSmithKline PLC Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze GlaxoSmithKline PLC ADR's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of GlaxoSmithKline PLC using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of GlaxoSmithKline PLC ADR based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 255.3 M | 268.1 M | |
| Total Revenue | 34.9 B | 19.9 B | |
| Cost Of Revenue | 9.8 B | 7.7 B | |
| Stock Based Compensation To Revenue | 0.01 | 0.01 | |
| Sales General And Administrative To Revenue | 0.36 | 0.39 | |
| Research And Ddevelopement To Revenue | 0.18 | 0.11 | |
| Capex To Revenue | 0.09 | 0.08 | |
| Revenue Per Share | 6.74 | 3.53 | |
| Ebit Per Revenue | 0.26 | 0.32 |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out GlaxoSmithKline PLC Piotroski F Score and GlaxoSmithKline PLC Altman Z Score analysis. You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of GlaxoSmithKline PLC. If investors know GlaxoSmithKline will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about GlaxoSmithKline PLC listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.167 | Dividend Share 0.61 | Earnings Share 1.55 | Revenue Per Share | Quarterly Revenue Growth 0.008 |
The market value of GlaxoSmithKline PLC ADR is measured differently than its book value, which is the value of GlaxoSmithKline that is recorded on the company's balance sheet. Investors also form their own opinion of GlaxoSmithKline PLC's value that differs from its market value or its book value, called intrinsic value, which is GlaxoSmithKline PLC's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because GlaxoSmithKline PLC's market value can be influenced by many factors that don't directly affect GlaxoSmithKline PLC's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between GlaxoSmithKline PLC's value and its price as these two are different measures arrived at by different means. Investors typically determine if GlaxoSmithKline PLC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, GlaxoSmithKline PLC's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.